Prometheus Biosciences, Inc. Common Stock

RXDX

Market cap $9.56B

Delisted

RXDX was delisted on the 15th of June, 2023.

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	MWNA 26 Marshall Wace North America New York	$1.45M	+$1.63M	+79,171	New
27	27 Goldman Sachs New York	$1.08M	+$1.22M	+59,083	New
28	28 Citadel Advisors Miami, Florida	$1.02M	+$1.16M	+56,138	New
29	29 Alyeska Investment Group Chicago, Illinois	$913K	+$1.03M	+50,000	New
30	LCM 30 Laurion Capital Management New York	$913K	+$1.03M	+50,000	New
31	KCM 31 Kingdon Capital Management New York	$730K	+$826K	+40,000	New
32	32 TD Asset Management Toronto, Ontario, Canada	$629K	+$712K	+34,465	New
33	PCM 33 Pinz Capital Management New York	$572K	+$646K	+31,300	New
34	34 Geode Capital Management Boston, Massachusetts	$324K	+$367K	+17,772	New
35	CCM 35 CAAS Capital Management New York	$274K	+$310K	+15,000	New
36	SCM 36 Silverarc Capital Management Boston, Massachusetts	$274K	+$310K	+15,000	New
37	HP 37 Hound Partners New York	$188K	+$213K	+10,292	New
38	MS 38 Maven Securities St Helier, Jersey	$152K	+$172K	+8,333	New
39	39 Bank of America Charlotte, North Carolina	$22K	+$25.4K	+1,228	New
40	40 UBS Group Zurich, Switzerland	$14K	+$16K	+776	New
41	41 Morgan Stanley New York	$5K	+$5.97K	+289	New